World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 7 October 2014
Main ID:  EUCTR2008-005320-81-BE
Date of registration: 20/02/2009
Prospective Registration: No
Primary sponsor: Novartis Pharma Services AG
Public title: A 2-year open-label second extension study to evaluate the safety, tolerability and efficacy of canakinumab (ACZ885) an anti-interleukin-1ß monoclonal antibody in patients with active rheumatoid arthritis - A2201E2
Scientific title: A 2-year open-label second extension study to evaluate the safety, tolerability and efficacy of canakinumab (ACZ885) an anti-interleukin-1ß monoclonal antibody in patients with active rheumatoid arthritis - A2201E2
Date of first enrolment: 16/02/2009
Target sample size:
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-005320-81
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: no Randomised: no Open: no Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: Placebo: Other:  
Phase: 
Countries of recruitment
Austria Belgium Germany Spain
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria:
Patients who completed the extension 1 study may enter the extension 2 study upon
signing informed consent.

A patient is defined as completing the extension 1 study if he/she completed the study up to and including Visit 31.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
Patients for whom continuation of treatment in the extension 2 is not considered
appropriate by the treating physician.

Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
female after conception and until the termination of gestation confirmed by a positive
hCG laboratory test (>5mIU/mL).

Women of childbearing potential (WOCBP) defined as all women physiologically capable of becoming pregnant, UNLESS they are: • Using a double barrier method of contraception such as intrauterine devices (IUDs), oral contraceptives, sub-dermal implants and a barrier method with spermicide, condoms. • Women whose partners have been sterilized by vasectomy or other means. • Considered post-menopausal and not of childbearing potential if they have had 24 months of natural (spontaneous) amenorrhea or six months of spontaneous amenorrhea with serum
FSH levels > 40 mIU/mL (for US only estradiol < 20 pg/mL) or have had surgical
bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.

Note: FSH and estradiol tests do not need to be performed for surgically sterile or women on estrogen replacement therapy. Females of childbearing potential must agree to continue to practice an acceptable form of birth control during the trial and for at least 2 months after completing the trial.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Rheumatoid Arthritis
MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis
Intervention(s)

Product Name: ACZ885
Product Code: ACZ885
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: Canakinumab
Current Sponsor code: ACZ885
Other descriptive name: Recombinant human monoclonal antibody to inerleukin-1beta of the IgG1-K-class
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-

Primary Outcome(s)
Main Objective: To assess long-term safety and tolerability of canakinumab (ACZ885) in patients with
active RA who completed the first extension study.
Secondary Objective: To evaluate the efficacy of canakinumab (ACZ885) by assessing the response to treatment according to ACR20, ACR50 and ACR70 criteria and DAS28.

To assess the effect of canakinumab on ACR components, including a marker of
inflammation (hsCRP).

To assess pharmacokinetic profile of canakinumab.

To assess immunogenicity of canakinumab.
Primary end point(s):
Secondary Outcome(s)
Secondary ID(s)
2008-005320-81-AT
CACZ885A2201E2
Source(s) of Monetary Support
Secondary Sponsor(s)
Novartis Pharma Belgium
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey